IMM CHART / SP, page-212

2021 Pipeline Updates: Upcoming Innovations in Non–Small Cell Lung CancerNovember 29, 2021:

IMMP up 7% in after hours trade.

Eftilagimod Alpha Expands Possibilities in Advanced NSCLCInvestigators recently announced that enrollment had completed across all cohorts for the expansion portion for part A of the phase 2 TACTI-002/KEYNOTE-798 trial (NCT03625323), assessing the role of LAG-3 fusion protein eftilagimod alpha (IMP321) plus pembrolizumab (Keytruda) in patients with unresectable/metastatic or PD-X refractory NSCLC.5 The trial includes a total of 185 patients in cohorts A (first-line NSCLC), B (second-line NSCLC), and C (second-line head and neck cancer).“The completion of recruitment for our Phase 2 TACTI-002 trial marks the achievement of a major milestone for Immutep. Our clinical team and partners have worked hard to continue the pace of patient enrollment and finished recruitment much earlier than originally anticipated, despite some challenging conditions brought on by the COVID-19 pandemic,” stated Marc Voigt, chief executive officer at Immustep, said in a press release. “We are excited to be reporting further results from this trial in the coming months. We sincerely thank the patients and their families, and our various partners, for their ongoing support of this important trial.”Findings from cohort A of the trial read out at the 2021 American Society of Clinical Oncology Annual Meeting,6 indicating that immunotherapy-naïve patients treated with eftilagimod alpha (n = 36) experienced a median progression-free survival of 8.2 months with a median OS that was not yet reached. Patients had a complete response rate of 6% by both blinded independent central review (BICR) and local read, as well as partial response rates of 36% and 31% in both respective groups. Patients had an overall response rate of 42% (95% CI, 25.5%-59.2%) by BICR and 36% (95% CI, 20.8%-53.8%) by local read. Investigators also reported disease control rates of 69% and 64% in both groups, respectively.References